# Endeavor BioMedicines: Biotechnology, San Diego, United States

> Endeavor BioMedicines: Endeavor BioMedicines is a clinical-stage biotechnology company based in San Diego, California, founded in 2019.

Source: https://millionrounds.com/startup/endeavor-biomedicines (Millionrounds; every figure on the page links to its filing or article)

United States · [Biotechnology startup](https://millionrounds.com/companies)

# Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage biotechnology company based in San Diego, California, founded in 2019.

Follow Endeavor BioMedicines and see its new rounds in your feed. [Sign up free](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fendeavor-biomedicines)

Funding reported Last round: Series C

Biotechnology San Diego, United States

Company summary

- **Founded:** 2018 8 years old
- **Team:** 53 51 to 200 people
- **Funding reported:** $296M in dollars
- **Last round:** Series C Apr 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Endeavor BioMedicines has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage biotechnology company based in San Diego, California, founded in 2019.

The company is dedicated to developing innovative therapies for patients with life-threatening diseases, focusing primarily on fibrotic lung disease and oncology. Its mission is to create treatments that may slow disease progression and potentially reverse the trajectory of intractable conditions. Endeavor BioMedicines is advancing two lead investigational candidates: ENV-101, a small-molecule inhibitor targeting idiopathic pulmonary fibrosis, and ENV-501, an antibody-drug conjugate for HER3-positive solid tumors. The company has initiated clinical trials for both candidates, with promising early results for ENV-101 in improving lung function in patients with pulmonary fibrosis. Endeavor operates within the drug discovery and biotechnology sectors, emphasizing research and development aimed at addressing the underlying causes of terminal diseases.

## What company datasets say Endeavor BioMedicines raised

Funding, as reported

Reported in all **$296M** in dollars

Rounds **3**

Last round **Series C**

Last round size **$133M**

Last round date **Apr 2024**

Investors listed **17**

SEC Form D **$222M sold, 2 filings, last May 2024**

## Founders and team

From Endeavor BioMedicines's own website and the SEC filings it signed: 9 on the team.

- **Anita DiFrancesco** Senior Vice President, Clinical Operations
- **Betsy Gelfand** Senior Vice President, Finance
- **Hutch Humphreys** Vice President, Regulatory Affairs
- **Randy Adams** Senior Vice President, Strategic Marketing & Communications
- **Vishaal Turakhia** Chief Financial Officer
- **Chris Krueger** Executive Officer i
- **Enoch Kariuki** Executive Officer i
- **John Hood** Executive Officer, Director i
- **Miguel de los Rios** Executive Officer i

On the board, as filed i *Bernard Davitian* *Karan Cheong Takhar* *Monal Cheong Mehta* *Patrick G. Enright* *Wing Cheong Lam*

## On a portfolio page

Investors who name them

- [Longitude Capital](https://millionrounds.com/fund/longitude-capital)

Each firm lists Endeavor BioMedicines on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care idiopathic pulmonary fibrosis transformational medicines disease trajectory reversal fibrotic disease therapy medical research oncology drugs phase 2a clinical trial post hoc analysis targeted therapy biotech leadership fibrosis reversal clinical research hospital & health care env-101 medical

Built with from their website

Google Tag Manager WordPress.org Font Awesome YouTube Max Mega Menu Viewport Meta CookieYes Babel OWL Carousel Priority Hints

+8 more

Google Font API imagesLoaded Microsoft Exchange MySQL PrimeNG wpBakery Microsoft 365 Apps & Services Mobile Friendly

- **Sector:** Biotechnology
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** California
- **Revenue:** $5.0M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/endeavor-biomedicines)

## Biotechnology in United States

Startups like it

- [**National Resilience** founded 2020 *Raised*](https://millionrounds.com/company/national-resilience)
- [**CREATE Medicines** Cambridge · founded 2019 *Raised*](https://millionrounds.com/company/create-medicines)
- [**AusperBio Therapeutics** Startup *Raised*](https://millionrounds.com/company/ausperbio-therapeutics)
- [**Nohla Therapeutics** Seattle · founded 2015 *Raised*](https://millionrounds.com/company/nohla-therapeutics)
- [**City Therapeutics** Startup *Raised*](https://millionrounds.com/company/city-therapeutics)
- [**Genapsys** Redwood City · founded 2010 *Raised*](https://millionrounds.com/company/genapsys)
- [**Proxima Bio** Startup *Raised*](https://millionrounds.com/company/proxima-bio)
- [**Infinimmune** Alameda · founded 2022 *Raised*](https://millionrounds.com/company/infinimmune)

## Is this your company?

Add your raise, your deck and your story, and put Endeavor BioMedicines in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)